CRBU Q4 2021 Earnings — Caribou Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CRBUCaribou Biosciences, Inc.

$186M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+160.1% YoY

Gross Profit

$2M89.3% margin

Operating Income

-$20M-797.4% margin

Net Income

-$18M-722.1% margin

EPS (Diluted)

$-0.31

QoQ Revenue Growth

-35.7%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$22M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$442M

Total Liabilities

$55M

Stockholders' Equity

$388M

Cash & Equivalents

$240M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$984,000	+160.1%
Gross Profit	$2M	-$11M	+120.7%
Operating Income	-$20M	-$15M	-34.1%
Net Income	-$18M	-$15M	-25.7%

Geographic Segments

UNITED STATES

$2M95%

Non-US

$129,0005%